Holder evidence
50
SEC ownership of RELMADA THERAPEUTICS, INC.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001553643.
Lead holder
JANUS HENDERSON GROUP PLC
13D/G signal
JANUS HENDERSON GROUP PLC
Latest evidence
27 Apr 2026
- CIK
- 0001553643
- Symbol
- RLMD on Nasdaq
- Location
- Coral Gables, FL
- SEC evidence mix
- 13F and 13D/G
- Lead holder
- JANUS HENDERSON GROUP PLC
- Latest large-stake holder
- JANUS HENDERSON GROUP PLC
- Latest evidence date
- 27 Apr 2026
Issuer identity
Ownership snapshot
Ownership snapshot
Top shareholders of RELMADA THERAPEUTICS, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Lead holder
JANUS HENDERSON GROUP PLC
13D/G signal
JANUS HENDERSON GROUP PLC
Evidence rows
50
Latest as of
27 Apr 2026
13F
13D/G
Lead comparable stake: 10%
13D/G row: JANUS HENDERSON GROUP PLC
Showing 1-8 of 50 holder rows.
Rank 1 holder
JANUS HENDERSON GROUP PLC
13F
13D/G
- Ownership
- 10%
- Position
- $76.89M
Rank 2 holder
Squadron Capital Management LLC
13F
13D/G
- Ownership
- 9.9%
- Position
- $58.98M
Rank 3 holder
Spruce Street Capital LP
13F
13D/G
- Ownership
- 5.6%
- Position
- $43M
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC |
13F
13D/G
Company
|
10%
from 13D/G
|
$76,892,206
11,063,862 shares
|
— | 31 Mar 2026 |
| Squadron Capital Management LLC |
13F
13D/G
Company · Squadron Master Fund LP
|
9.9%
from 13D/G
|
$58,983,014
8,474,571 shares
|
— | 31 Mar 2026 |
| Spruce Street Capital LP |
13F
13D/G
Company
|
5.6%
from 13D/G
|
$42,998,208
6,262,114 shares
|
— | 31 Mar 2026 |
| Commodore Capital LP |
13D/G
13F
Company
|
5.1%
|
$40,630,789
5,505,527 shares
|
$0 | 27 Apr 2026 |
| Ikarian Capital, LLC |
13F
13D/G
Company
|
4.8%
from 13D/G
|
$18,710,978
2,688,359 shares
|
— | 31 Mar 2026 |
| Adage Capital Management, L.P. |
13D/G
|
4.5%
|
$35,152,106
4,763,158 shares
|
+$3,639,506 | 31 Mar 2026 |
| Venrock Adviser, LLC |
13F
Company
|
4.6%
|
$33,709,925
4,843,380 shares
|
— | 31 Mar 2026 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
Company
|
4.5%
|
$33,151,580
4,763,158 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$2,536,155.
Buys
$2,536,155
Insiders: 4
Sells
$0
Insiders: 0
Net
+$2,536,155
Shares: +1,303,641
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 1,303,641
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 39,165 | 0 | $161,360 | $0 | +$161,360 |
| 6-9 | 998,500 | 0 | $2,196,700 | $0 | +$2,196,700 |
| 9-12 | 265,976 | 0 | $178,095 | $0 | +$178,095 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-9 of 9 reporting-owner rows connected to RELMADA THERAPEUTICS, INC.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
9
Lead holder
Sergio Traversa
Net 12M change
+$2,536,155
Latest report
12 Dec 2025
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Sergio Traversa | Chief Executive Officer, Director | $5,356,000 | +$890,895 | +20% | Filing P/S | 12 Dec 2025 |
| Maged Shenouda | Chief Financial Officer | $3,296,000 | +$1,148,060 | +53% | Filing P/S | 12 Dec 2025 |
| Paul Edward Kelly | COO, Director | $1,105,049 | +$198,000 | +22% | Filing P/S | 12 Dec 2025 |
| Chuck Ence | CA and CO | $888,648 | +$299,200 | +51% | Filing P/S | 12 Dec 2025 |
| Cedric O'Gorman | Chief Medical Officer | $32,185 | Filing P/S | 23 May 2023 | ||
| Fabiana Fedeli | Director | Mixed | 12 Dec 2025 | |||
| Charles J. Casamento | Director | Mixed | 12 Dec 2025 | |||
| John Glasspool | Director | Mixed | 12 Dec 2025 | |||
| Eric Thomas Schmidt | Director | Mixed | 25 May 2023 |
Recent insider transactions for RELMADA THERAPEUTICS, INC.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Reported value | Reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Sergio Traversa | RLMD | Common Stock | Purchase | 2.16% | $113,300 | $4.12 | 27,500 | 1,300,000 | 15 Dec 2025 | Direct |
| Maged Shenouda | RLMD | Common Stock | Purchase | 1.48% | $48,060 | $4.12 | 11,665 | 800,000 | 15 Dec 2025 | Direct |
| Sergio Traversa | RLMD | Stock Appreciation Rights | Award | 1,198,000 | 1,198,000 | 12 Dec 2025 | Direct | |||
| Maged Shenouda | RLMD | Stock Appreciation Rights | Award | 828,000 | 828,000 | 12 Dec 2025 | Direct | |||
| Chuck Ence | RLMD | Stock Appreciation Rights | Award | 828,000 | 828,000 | 12 Dec 2025 | Direct | |||
| Fabiana Fedeli | RLMD | Stock Appreciation Rights | Award | 164,000 | 164,000 | 12 Dec 2025 | Direct | |||
| John Glasspool | RLMD | Stock Appreciation Rights | Award | 164,000 | 164,000 | 12 Dec 2025 | Direct | |||
| Paul Edward Kelly | RLMD | Stock Appreciation Rights | Award | 828,000 | 828,000 | 12 Dec 2025 | Direct | |||
| Charles J. Casamento | RLMD | Stock Appreciation Rights | Award | 164,000 | 164,000 | 12 Dec 2025 | Direct | |||
| Chuck Ence | RLMD | Common Stock | Purchase | 50.8% | $299,200 | $2.20 | 136,000 | 403,931 | 05 Nov 2025 | Direct |
| Sergio Traversa | RLMD | Common Stock | Purchase | 27.2% | $599,500 | $2.20 | 272,500 | 1,272,500 | 05 Nov 2025 | Direct |
| Maged Shenouda | RLMD | Common Stock | Purchase | 173.4% | $1,100,000 | $2.20 | 500,000 | 788,335 | 05 Nov 2025 | Direct |
| Paul Edward Kelly | RLMD | Common Stock | Purchase | 21.8% | $198,000 | $2.20 | 90,000 | 502,295 | 05 Nov 2025 | Direct |
| Sergio Traversa | RLMD | Common Stock | Purchase | 5.93% | $41,422 | $0.7400 | 55,976 | 1,000,000 | 28 Aug 2025 | Direct |
| Sergio Traversa | RLMD | Common Stock | Purchase | 15.9% | $86,735 | $0.6700 | 129,455 | 944,024 | 27 Aug 2025 | Direct |
| Sergio Traversa | RLMD | Common Stock | Purchase | 11% | $49,938 | $0.6200 | 80,545 | 814,569 | 26 Aug 2025 | Direct |
| Chuck Ence | RLMD | Stock Option (right to buy) | Award | 400,000 | 400,000 | 26 Jun 2025 | Direct | |||
| Maged Shenouda | RLMD | Stock Option (right to buy) | Award | 600,000 | 600,000 | 26 Jun 2025 | Direct | |||
| Sergio Traversa | RLMD | Stock Option (right to buy) | Award | 800,000 | 800,000 | 26 Jun 2025 | Direct | |||
| Charles J. Casamento | RLMD | Stock Option (right to buy) | Award | 100,000 | 100,000 | 26 Jun 2025 | Direct | |||
| John Glasspool | RLMD | Stock Option (right to buy) | Award | 100,000 | 100,000 | 26 Jun 2025 | Direct | |||
| Fabiana Fedeli | RLMD | Stock Option (right to buy) | Award | 100,000 | 100,000 | 26 Jun 2025 | Direct | |||
| Paul Edward Kelly | RLMD | Stock Option (right to buy) | Award | 400,000 | 400,000 | 26 Jun 2025 | Direct |
* indicates a reported price that failed the local validity check.